Silo Pharma sets 1-for-15 reverse stock split

Silo Pharma is implementing a 1-for-15 reverse stock split of its common stock, with a concurrent proportional cut in authorized shares.

Rhea-AI Filing Summary

Silo Pharma is implementing a 1-for-15 reverse stock split of its common stock, with a concurrent proportional cut in authorized shares. The split becomes effective as of 4:01 p.m. Eastern Time on June 2, 2026, and shares will begin trading on a post-split basis on June 3, 2026 under the same symbol, SILO.

Every 15 pre-split shares will be exchanged for 1 post-split share, with fractional positions rounded up to the next whole share. The company expects issued and outstanding shares to decrease from approximately 16.267 million to about 1.084 million. Authorized common stock will be adjusted to 6,666,667 shares, and the share amounts and exercise prices for equity awards, warrants, and plan reserves will be adjusted proportionately.

Insights

Capital structure analyst

Silo Pharma is consolidating its share count via a 1-for-15 reverse split with matching authorized share reduction.

The company is exchanging every fifteen outstanding common shares for one new share, rounding any fractional holdings up. This cuts outstanding shares from approximately 16.267 million to about 1.084 million, while also reducing authorized common stock to 6,666,667 shares.

Reverse splits typically change the per-share price and share count without altering total company value by themselves. Proportional adjustments to equity awards, warrants, and plan reserves mean existing derivative securities maintain their relative economic terms after the effective date of June 2, 2026.

8-K Event Classification

Item 8.01 — Other Events

1 item

Item 8.01 Other Events Other

Voluntary disclosure of events the company deems important to shareholders but not covered by other items.

Key Figures

Reverse split ratio: 1-for-15 Outstanding shares pre-split: Approximately 16.267 million shares Outstanding shares post-split: Approximately 1.084 million shares +4 more

7 metrics

Reverse split ratio 1-for-15 Each 15 shares exchanged for 1 share

Outstanding shares pre-split Approximately 16.267 million shares Issued and outstanding common stock before reverse split

Outstanding shares post-split Approximately 1.084 million shares Issued and outstanding common stock after reverse split

Authorized common stock post-split 6,666,667 shares Authorized common stock after proportional reduction

Effective time 4:01 p.m. Eastern Time Reverse split effective on June 2, 2026

Post-split trading start June 3, 2026 First trading day on post-split basis on Nasdaq Capital Market

New CUSIP 82711P 300 CUSIP for common stock after reverse split

Key Terms

reverse stock split, authorized common stock, equity awards, warrants, +2 more

6 terms

reverse stock split financial

"it will effect a 1-for-15 reverse split of its issued and outstanding common stock"

A reverse stock split reduces a company's number of outstanding shares while raising the price per share proportionally, so the total value of each investor's holding is unchanged; a 1-for-10 split turns 100 shares worth $1 each into 10 shares worth $10 each. Companies often do this to regain compliance with an exchange's minimum price rule or to attract investors who avoid very low-priced stocks.

authorized common stock financial

"a concurrent proportionate reduction of its authorized common stock"

equity awards financial

"Equitable adjustments will be made to the number of shares of the Company’s common stock issuable upon exercise of the Company’s equity awards"

Equity awards are payments to employees or directors made in the form of company stock or rights to buy stock later, serving as a way to share ownership rather than cash. For investors, they matter because they align staff incentives with company performance, can increase the number of shares outstanding over time (which can reduce each share’s claim on profits), and create compensation costs that affect reported earnings.

warrants financial

"Equitable adjustments will be made to the number of shares of the Company’s common stock issuable upon exercise of the Company’s equity awards, and warrants"

Warrants are special documents that give you the right to buy a company's stock at a set price before a certain date. They are often used as a way for companies to attract investors or raise money, and their value can increase if the company's stock price goes up.

equity incentive plans financial

"and the number of shares issuable under the Company’s equity incentive plans"

Equity incentive plans are company programs that pay employees, executives, or directors with company stock, stock options, or share units instead of or in addition to cash, aiming to align their interests with shareholders—like giving team members a stake in the house they help build. For investors this matters because such plans can motivate better company performance but also dilute existing ownership and increase reported compensation costs, so they affect future earnings, voting power, and share value.

Emerging growth company regulatory

"Emerging growth company"

An emerging growth company is a recently public or smaller public firm that qualifies for temporary, lighter regulatory and disclosure rules to reduce the cost and effort of being public. For investors, it means the company may provide less historical financial detail and face fewer reporting requirements than larger firms, so it can grow more quickly but also carries higher uncertainty—like buying a promising early-stage product with fewer user reviews.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What reverse stock split did Silo Pharma (SILO) announce on June 1, 2026?

Silo Pharma approved a 1-for-15 reverse stock split of its common stock. Every fifteen existing shares will be converted into one new share, consolidating the share count while keeping the same Nasdaq Capital Market ticker, SILO.

When will Silo Pharma’s 1-for-15 reverse split become effective and begin trading?

The reverse split becomes effective at 4:01 p.m. Eastern Time on June 2, 2026. Post-split shares will begin trading on The Nasdaq Capital Market on June 3, 2026, under the same trading symbol, SILO.

How does Silo Pharma’s reverse split affect its outstanding share count?

After the 1-for-15 reverse split, Silo Pharma expects outstanding common shares to decline from approximately 16.267 million to about 1.084 million. This reflects the 15-to-1 consolidation while preserving each holder’s proportional ownership in the company.

What happens to fractional shares in Silo Pharma’s reverse stock split?

Any fractional shares created by the 1-for-15 reverse split will be rounded up to the next higher whole share. This means shareholders will not hold fractional post-split shares; instead, they will receive one full share when a fraction would otherwise result.

How will Silo Pharma’s authorized common stock change after the reverse split?

Concurrent with the reverse split, Silo Pharma will proportionally reduce its authorized common stock. After the effective time, the company will have 6,666,667 authorized common shares, aligning the capital structure with the smaller outstanding share base.

What is the new CUSIP number for Silo Pharma’s post-split common stock?

Following the reverse stock split, Silo Pharma’s common stock will have a new CUSIP number, 82711P 300. The shares will continue trading on The Nasdaq Capital Market under the SILO symbol, reflecting only a change in identification, not in listing venue.

How are Silo Pharma’s equity awards and warrants affected by the reverse split?

Silo Pharma will make equitable adjustments to equity awards, warrants, and equity incentive plan shares. The number of shares underlying these instruments and their exercise prices will be proportionately modified, preserving their relative economic value after the 1-for-15 reverse split.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Understanding 8-K Material Events →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Accepted by SEC EDGAR 06/01/2026 - 09:02 AM Learn about SEC filing dates

false 0001514183 0001514183 2026-06-01 2026-06-01 iso4217:USD xbrli:shares iso4217:USD xbrli:shares

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 8-K

CURRENT REPORT

Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): June 1, 2026

Silo Pharma, Inc.

(Exact name of registrant as specified in its charter)

Nevada		001-41512		27-3046338
(State or other jurisdiction of incorporation)		(Commission File Number)		(IRS Employer Identification No.)

677 N. Washington Boulevard Sarasota, FL		34236
(Address of principal executive offices)		(Zip Code)

Registrant’s telephone number, including area code: (718) 400-9031

N/A

(Former name or former address, if changed since last report)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):

☐ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

☐ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

☐ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Rule 12(b) of the Act:

Title of each class		Trading Symbol(s)		Name of exchange on which registered
Common Stock, par value $0.0001 per share		SILO		The Nasdaq Stock Market LLC

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

Emerging growth company ☐

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

Item 8.01 Other Events.

Silo Pharma, Inc. (the “Company”) today announced that it will effect a 1-for-15 reverse split of its issued and outstanding common stock with a concurrent proportionate reduction of its authorized common stock effective as of 4:01 p.m. Eastern Time on June 2, 2026. Commencing with the opening of trading on The Nasdaq Capital Market on June 3, 2026, the Company’s common stock will trade on a post-split basis under the same trading symbol, “SILO”.

As a result of the reverse stock split, the CUSIP number for the Company’s common stock will be 82711P 300 and every fifteen (15) shares of issued and outstanding Company common stock will be exchanged for one (1) share of Company common stock with any fractional shares being rounded up to the next higher whole share. Once effective, the reverse stock split will reduce the current number of issued and outstanding shares of common stock from approximately 16.267 million to approximately 1.084 million. Equitable adjustments will be made to the number of shares of the Company’s common stock issuable upon exercise of the Company’s equity awards, and warrants and the number of shares issuable under the Company’s equity incentive plans, as well as the applicable exercise prices for such equity awards and warrants, in accordance with their terms. In addition, concurrent with the reverse stock split, a proportionate reduction will be made to the Company’s authorized shares of common stock such that the Company shall have 6,666,667 shares of authorized common stock after the effective time of the reverse stock split.

1

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

	SILO PHARMA, INC.
Date: June 1, 2026	By:	/s/ Eric Weisblum
		Eric Weisblum
		Chief Executive Officer

2

Filing Exhibits & Attachments

3 documents

Other Documents

• EX-101 XBRL SCHEMA FILE 2.9 KB
• EX-101 XBRL LABEL FILE 33.4 KB
• EX-101 XBRL PRESENTATION FILE 21.8 KB